Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventative Treatment of Episodic Migraine in Pe

Clinical Trial Grant
Duke Scholars

Administered By

School of Medicine

Awarded By

Teva Branded Pharmaceutical Products R&D, Inc

Start Date

January 4, 2022

End Date

January 31, 2027
 

Administered By

School of Medicine

Awarded By

Teva Branded Pharmaceutical Products R&D, Inc

Start Date

January 4, 2022

End Date

January 31, 2027